---
layout: default
title: Collaborations
subtitle: Collaborative projects
---

I serve as the co-investigator/collaborator, and provides bioinformatics supports for these projects:

**Active**

---

**Title**: Alliance Statistics and Data Management Center
+ **Funding Mechanism**: U10
+ **Source of Support**: NIH/NCI
+ **Start and End Date**: 2021-2025
+ **PI**: Mandrekar

**Title**: Mayo Comprehensive Cancer Center Grant
- **Funding Mechanism**: P30
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2021 \- 2024
- **PI**: Fonseca

- **Title**: Discovery and validation of non-invasive epigenetic biomarkers for AATD liver disease
- **Funding Mechanism**: Foundation
- **Source of Support**: Alpha 1 foundation
- **Start and End Date**: 2020 \- 2021
- **PI**: Robertson

- **Title**: Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NIAAA
- **Start and End Date**: 2018 \- 2023
- **PI**: Robertson

- **Title**: Epigenetic Mechanisms Underlying Hepatitis C-Induced Hepatocarcinogenesis
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2017 \- 2022
- **PI**: Robertson

- **Title**: Deciphering the interplay between H3K36 and DNA methylation in renal cancer
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2018 \- 2023
- **PI**: Robertson

- **Title**: Understanding the interactions between germline and somatic alterations in the pathogenesis of gliomas
- **Funding Mechanism**: RO1
- **Start and End Date**: 2018 \- 2023
- **Source of Support**: NIH/NCI
- **PI**: Jenkins

- **Title**: Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2018 \- 2023
- **PI**: Huang

- **Title**: Role of FOXO1 Inactivation in Prostate Tumorigenesis
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2015 \- 2021
- **PI**: Huang

- **Title**: Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2017 \- 2022
- **PI**: Huang

- **Title**: Migraine genomic marker discovery
- **Funding Mechanism**: Benefactor
- **Source of Support**:  Gifts from benefactors
- **Start and End Date**: 2019 - 2024
- **PI**: Cutrer

**Completed**

---

- **Title**: Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression
- **Funding Mechanism**: RO1
- **Source of Support**: NIH/NCI
- **Start and End Date**: 2015 \- 2020
- **PI**: Huang

- **Title**: The role of EZH2 in PTEN-deficient prostate cancer pathogenesis and therapy
- **Funding Mechanism**: DOD
- **Source of Support**: U.S. Department of Defense
- **Start and End Date**: 2014 \- 2017
- **PI**: Huang

- **Title**: Targeting aberrant AR-FL and AR-V expression and activity to overcome therapy resistance in metastatic castration-resistant prostate cancer
- **Funding Mechanism**: Foundation
- **Source of Support**: Prostate Cancer Foundation (PCF)
- **Start and End Date**: 2014 \- 2017
- **PI**: Huang




